Literature DB >> 26089624

Age-Related Changes in Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR1) and Receptor 2 (sVEGFR2) in Healthy Japanese Subjects.

Yoshihiro Okamoto1, Tomoyo Mita1, Testuri Kodama1, Yoshimitsu Gotoh2, Naoya Fujita3, Takashi Fukui1, Toshiyuki Masuzawa1.   

Abstract

We measured serum soluble vascular endothelial growth factor receptor 1 (sVEGFR1) and receptor 2 (sVEGFR2) levels in healthy Japanese individuals in order to establish a reference value using a specific ELISA. Significant differences were observed in serum sVEGFR1 and sVEGFR2 levels between children and adults. To demonstrate the usefulness of the reference value for children, we measured serum sVEGFR1 and sVEGFR2 levels in children with diarrhea positive (D+) hemolytic uremic syndrome (HUS) as a preliminary study. Serum sVEGFR2 levels in children with HUS were markedly higher than those in healthy children from the onset of D + HUS. The reference value for healthy children in the present study will allow normal and pathological conditions to be discriminated from each other in future study.

Entities:  

Keywords:  Endothelial growth factor (VEGF); Hemolytic uremic syndrome (HUS); Soluble VEGF receptor-1 (sVEGFR1); Soluble VEGF receptor-2 (sVEGFR2); Vascular

Year:  2014        PMID: 26089624      PMCID: PMC4469059          DOI: 10.1007/s12291-014-0463-z

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  13 in total

Review 1.  Mechanisms of soluble cytokine receptor generation.

Authors:  Stewart J Levine
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

Review 2.  The biology of vascular endothelial growth factor.

Authors:  N Ferrara; T Davis-Smyth
Journal:  Endocr Rev       Date:  1997-02       Impact factor: 19.871

3.  Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients.

Authors:  Shogo Kikuchi; Yuki Obata; Kiyoko Yagyu; Yingsong Lin; Toshifusa Nakajima; Osamu Kobayashi; Masahiro Kikuichi; Ryo Ushijima; Michiko Kurosawa; Junko Ueda
Journal:  Cancer Sci       Date:  2011-02-15       Impact factor: 6.716

Review 4.  Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.

Authors:  Masabumi Shibuya
Journal:  J Biochem Mol Biol       Date:  2006-09-30

5.  Age-dependent decrease in serum soluble interferon-gamma receptor (sIFN-gammaR) in healthy Japanese individuals; population study of serum sIFN-gammaR level in Japanese.

Authors:  Yoshihiro Okamoto; Kyoko Seta; Izumi Nakajo; Yoshimitsu Gotoh; Takuhito Nagai; Naoya Fujita; Takashi Fukui; Toshiyuki Masuzawa
Journal:  J Immunoassay Immunochem       Date:  2008

Review 6.  [Guidelines for the diagnosis and treatment of hemolytic uremic syndrome (HUS) with enterohemorrhagic colitis (Japanese Society of Pediatric Nephrology)].

Authors:  Mitsuru Okada; Tsukasa Takemura
Journal:  Nihon Rinsho       Date:  2003-02

7.  Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS.

Authors:  D Maroeska Te Loo; Nienke Bosma; Victor Van Hinsbergh; Paul Span; Rob De Waal; Ruud Clarijs; C Sweep; Leo Monnens; Lambertus Van Den Heuvel
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

8.  The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis.

Authors:  Yue-Ting Tang; Fang Jiang; Li Guo; Meng-Ya Si; Xiao-Yang Jiao
Journal:  J Neurooncol       Date:  2013-02-12       Impact factor: 4.130

9.  The dynamics of angiogenic factors and their soluble receptors in relation to organ dysfunction in disseminated intravascular coagulation associated with sepsis.

Authors:  Subrina Jesmin; Takesi Wada; Satoshi Gando; Sayeeda Sayeeda Sultana; Sohel Zaedi
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

10.  Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988. The Canadian Pediatric Kidney Disease Reference Centre.

Authors:  P C Rowe; E Orrbine; G A Wells; P N McLaine
Journal:  J Pediatr       Date:  1991-08       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.